Docetaxel/cisplatin
Original Article c-Jun and Camk2a contribute to the drug resistance of induction docetaxel/cisplatin/5-fluorouracil in hypopharyngeal carcinoma
... Induction docetaxel/cisplatin/5 fluorouracil (TPF) chemo- therapy is regarded as the standard of treatment for locoregionally advanced ...to cisplatin suffer, rather than benefit, from chemotherapy ...
9
Original Article Efficacy and safety of docetaxel, cisplatin and fluorouracil regimen compared with epirubicin, cisplatin and fluorouracil regimen for gastric carcinoma: a meta-analysis
... In this study, we conducted a meta-analysis to determine the efficacy and safety of docetaxel, cisplatin and fluorouracil (DCF) regimen com- pared with epirubicin, cisplatin and fluorouracil (ECF) ...
12
Betel nut chewing history is an independent prognosticator for smoking patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil
... of cisplatin and fluorouracil (PF), the novel induction chemotherapy regi- men of docetaxel, cisplatin, and fluorouracil (TPF) signifi- cantly increased survival for patients with locally advanced ...
9
Preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for locally advanced esophageal carcinosarcoma: a case report and review of the literature
... Esophagogastroduodenoscopy (EGD) revealed a polypoid neoplasm combined with an infiltrative ulcer that exhibited a mixture of squamous cell carcinoma and spindle cell sarcoma histologically. Computed tomography findings ...
7
Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with concurrent weekly cisplatin chemoradiotherapy for locally advanced head and neck squamous cell carcinoma
... induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with cisplatin concurrent chemoradiotherapy for nonmetastatic Stage IV head-and-neck squamous cell ...
30
Phase II study of docetaxel, cisplatin, and fluorouracil in patients with distantly metastatic penile cancer as first-line chemotherapy
... of docetaxel, cisplatin and fluorouracil has shown high activity in head and neck squamous cancer and other cancer treatments which showed histopathologic similarity to penile squamous cancer [15, ...
8
Neoadjuvant modified TPF (docetaxel, cisplatin, fluorouracil) for patients unfit to standard TPF in locally advanced head and neck squamous cell carcinoma: a study of 48 patients
... TPF (docetaxel, cisplatin, fluorouracil) is the standard chemotherapy used for induction in locally advanced head and neck squamous cell carcinoma (LAHNSCC). Its toxicity limits it to younger patients with ...
8
Management of Hematologic Toxicity in Patients with Advanced or Metastatic Gastric Cancer Treated with Docetaxel, Cisplatin and Fluorouracil (DCF): Results of Monocentric Experience
... In summary, the V325 randomized phase III trial results in a significantly better preservation of QoL for patients treated with DCF than patients treated with CF. In this study, better preservation of QoL occurred as a ...
5
Risk factors for febrile neutropenia and effectiveness of primary prophylaxis with pegfilgrastim in patients with esophageal cancer treated with docetaxel, cisplatin, and 5 fluorouracil
... All patients in this study received DCF therapy as initial treatment for esophageal cancer. The regimen in this study was docetaxel as 1-h 75 mg/m 2 I.V. infusion on day 1, cisplatin 75 mg/m 2 I.V. infusion ...
6
Outcomes of esophagectomy after chemotherapy with biweekly docetaxel plus cisplatin and fluorouracil for advanced esophageal cancer: a retrospective cohort analysis
... Recent studies have reported that combination chemo- therapy using docetaxel/cisplatin/5-fluorouracil (DCF) is effective as preoperative chemotherapy for advanced esophageal cancer [1–4]. Hara et al. [2] ...
9
NC-6301, a polymeric micelle rationally optimized for effective release of docetaxel, is potent but is less toxic than native docetaxel in vivo
... 14 docetaxel (DTX) molecules per polymer: (A) size distribution – the average diameter was 120–130 nm, with minor disparities; (B) release of DTX as a function of time during incubation in fresh human serum (•) or ...
15
PP2A inhibition with LB100 enhances cisplatin cytotoxicity and overcomes cisplatin resistance in medulloblastoma cells
... total cisplatin uptake with LB100 treatment on ...of cisplatin sensitivity could be at least partially related to a direct increase in cisplatin ...increased cisplatin uptake is alteration of ...
17
Original Article Concurrent chemoradiotherapy with weekly docetaxel and cisplatin versus docetaxel and nedaplatin for locally advanced esophageal carcinoma
... as cisplatin (DPP), exhibiting higher activity against certain solid tumors as well as lower nephrotoxicity and gastrointestinal toxicity ...the cisplatin-resistant human leukemia cell lines was responsive ...
10
Docetaxel Chemotherapy of Korean Patients with Hormone refractory Prostate Cancer : Comparative Analysis between 1st line and 2nd line Docetaxel
... were required to continue androgen blockade with a luteinizing hormone-releasing hormone (LHRH) analogue. Patients underwent physical examination, CBC, LFT and renal function test before docetaxel administration, ...
8
Use of a multi-drug regimen gemcitabine, 5-fluorouracil, irinotecan, cisplatin, bevacizumab, docetaxel, and cyclophosphamide (GFIP/BDC) for heavily pretreated relapsed epithelial ovarian, fallopian tube and primary peritoneal cancer
... leucovorin, cisplatin and 5-fluorouracil (G-FLIP) in 34 patients ...of cisplatin by formation of DNA adducts when given 24 h after gemcitabine infusion [10 – ...of cisplatin by inhibiting ...
7
Cisplatin inhibits MEK1/2
... Cisplatin (cDDP) is widely used for the treatment of many types of cancer. It is a polar molecule that does not readily diffuse across bilayer lipid membranes as shown by the fact that it remains stably ...
13
How nanotechnology can enhance docetaxel therapy
... Abstract: Docetaxel has been recognized as one of the most efficient anticancer drugs over the past decade; however, its poor water solubility and systemic toxicity have greatly limited its clinical ...for ...
15
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2 positive breast cancer
... Association between median biomarker levels and pCR In the overall biomarker population (Fig. 1 and Add- itional file 1: Table S3), high HER2 membrane protein expression, measured by modified H-score and stratified by ER ...
12
Identifying intracellular cisplatin interaction partners and assessing their contribution to cisplatin resistance
... evaluated. Cisplatin was administered intraperitoneally after a cytoreductive surgery in an attempt to kill residual cancer cells by an elevated local cisplatin exposition ...Therefore, cisplatin is ...
154
Docetaxel induced changes in cholesterol profile: Role of Morin
... on docetaxel-induced changes in cholesterol profile in ...that docetaxel had the capacity to produce changes in cholesterol ...on docetaxel-induced changes in cholesterol ...
5